NCT02568176View on ClinicalTrials.gov

Pharmacokinetic Study of Intranasal Esketamine and Its Effects on the Pharmacokinetics of Orally-Administered Midazolam and Bupropion in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions

Healthy

Interventions

DRUG

Midazolam

Single oral dose of midazolam 6 mg Day 1 and Day 17.

DRUG

Esketamine

Intranasal esketamine will be self-administered 5 times during 15 days.

DRUG

Bupropion

Single oral dose of bupropion 150 mg on Day 1 and 19.

Trial Locations (1)

Unknown

Merksem

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT02568176 - Pharmacokinetic Study of Intranasal Esketamine and Its Effects on the Pharmacokinetics of Orally-Administered Midazolam and Bupropion in Healthy Participants | Biotech Hunter | Biotech Hunter